Advertisement
Advertisement
ARGX
argenx SE - ADR
971.55
USDSponsored
+9.28
+0.96%
Nov 10, 15:59 UTC -5
Closed
After-Market
972.38
+0.84
+0.09%
argenx SE - ADR (ARGX) Earnings
ARGX Earnings Reports
Positive Surprise Ratio
ARGX beat 24 of 43 last estimates.
56%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
argenx SE - ADR earnings per share and revenue
On Oct 22, 2026, ARGX reported earnings of 7.80 USD per share (EPS) for Q3 26, missing the estimate of 8.22 USD, resulting in a -5.20% surprise. Revenue reached 1.75 billion, compared to an expected 1.70 billion, with a 3.06% difference. The market reacted with a -1.61% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Legend Biotech Corporation - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
$0.00
Actual
$0.13
Surprise
+9,900.00%
Hemab Therapeutics Holdings, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.53
Actual
-$0.57
Surprise
-8.51%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Opus Genetics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.18
Surprise
-19.68%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
MaxCyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.07
Actual
-$0.05
Surprise
+36.79%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were argenx SE - ADR's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, argenx SE - ADR reported EPS of $7.80, missing estimates by -5.2%, and revenue of $1.75B, 3.06% above expectations.
How did the market react to argenx SE - ADR's Q3 2026 earnings?
The stock price moved down -1.61%, changed from $890.05 before the earnings release to $875.76 the day after.
When is argenx SE - ADR expected to report next?
The next earning report is scheduled for --.
What are the forecasts for argenx SE - ADR's next earnings report?
Based on --
analysts, argenx SE - ADR is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.